{"id":904378,"date":"2025-11-03T11:41:05","date_gmt":"2025-11-03T16:41:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/"},"modified":"2025-11-03T11:41:05","modified_gmt":"2025-11-03T16:41:05","slug":"corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/","title":{"rendered":"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1\/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting &amp; Exposition, which is taking place December 6-9, 2025 in Orlando, FL.<\/p>\n<p>Details regarding the oral presentation are as follows:<\/p>\n<p>\n        <strong>Session Name:<\/strong> 625. T Cell, NK Cell, or NK\/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell Lymphoma<br \/><strong>Session Date:<\/strong> December 8, 2025<br \/><strong>Session Time:<\/strong> 10:30 AM &#8211; 12:00 PM<br \/><strong>Presentation Time:<\/strong> 11:15 AM &#8211; 11:30 AM<br \/><strong>Publication Number:<\/strong> 778<br \/><strong>Title:<\/strong> Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed\/refractory (R\/R) T cell lymphomas (TCL)<\/p>\n<p>\n        <strong>About\u00a0Corvus Pharmaceuticals<\/strong>\u00a0<br \/>Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is now in a registration Phase 3 clinical trial for relapsed\/refractory T cell lymphoma and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KpPNHFZ_XmNO07RfaAm-hoJ7EAOJ6h5M_kUIoy1ttUD4pIpc8GEMcdLrU7W_LMUvQbn-XTBoJu36jRyMUCbie4EW7G5KglFsxXyc3WuyqnDMm0PBu6CeLkivixXsi52RZGl_8beqzTYss2K-6Pu6Gm1LBvfH7oPrxBuxcOumYz4gobQquGFyngezw0VvAX5TbrP_QNV-RBxPPalZOkDTNWwE7xo74uUnAYCxy2yWzJxjifI45btx4A5oRzCtyFpv85y2ynhjsgdYxZkTL_ke3w==\" rel=\"nofollow\" target=\"_blank\">www.corvuspharma.com<\/a>\u00a0or follow the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G-aomPANpToeG-kvqPIxQe6yMTqNWqmoLiU05zTFYAmzvvUgRMbF4v_RbDfWvwzw2se8HzQMGzw22BrTklVGT_cZRol13ka0DoGLaARE-gh6iXxdPu6m5vMT_f_FIFZmOy1IRmGuaPexMPB4Gqft0_BDWgPA6HsSiVBOyVrPa4-z-s1HekmNZ0Qws9ezaYP0gtsUFlo1Z7gA7Kpsp_zwd7_uVn0sxcBDybt3erE1K4yaMzvms5tXaL8nxW7qteunAQqlc3hUsip0jYhO-Gli4w==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>INVESTOR CONTACT:<br \/>Leiv Lea<br \/>Chief Financial Officer<br \/>Corvus Pharmaceuticals, Inc.<br \/>+1-650-900-4522<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tl4oQkrRNoCW6b5CaRC2SNm7aHtlnkE15dPoLeMiTHm7OEOwXFaTsOhbcU_wWlvj10vcKYS5_RWoqphsLKKjph_VCZpVfF5svBA8I2-JkWE_u7zspf9ZRZjEqcfYTOPZ4Za7SJntdWKKfLpOCKIsz2y5J5Hcg_q5Afzop0ugJr4pDt2RvZXwktBESGlaJCUhfezmE22GZVISsWnbG7t0LSm4JBmH7NPFbeZQadcVzbFe-j52G9XRBQ7SBcTETWT72ijSvdCBRlpAFyQx0tgFKGVpOB5B-w8uhtoERS8b_zplzlajeouNNQsYvDcd7PDhoMIEgt6fVLsc1sMaD2CGIr4P6qVUi9xVTob5PUqSFuyAqwH5HylAbzKOgnSMLb8rui_ziBvXExEk4GMcUEEL1oWpDpqkOHU7KedcV_AzVi-XO43EYYw7qwNYW6nHLBNd06qHbopsvncv5p61tpcgKDF2zg6TVs6R8Q6woc84vIXE-R8kvcyhugqQHtPJo8n7\" rel=\"nofollow\" target=\"_blank\">llea@corvuspharma.com<\/a><\/p>\n<p>MEDIA CONTACT:<br \/>Sheryl Seapy<br \/>Real Chemistry<br \/>+1-949-903-4750<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJTE2HkdH6pxRHWAlP8mCm-NXSxX0v1LU1xnbCz-A9Zo-yRGM9LGfp4zxt4sSXqvcaqJiPBvyylctvfi7FZLgyEi3Wk9hztmxQroJb8FGvElmaRY5k82IWiC7wEx8IJ4F11X8Gfp3PS_TQ7uYcFKDsSEud5IePg1YxsQ6XXBFCDyi1LALeyepz7T2u9nFOaR6_QeSDf707346ize98yWYn8nD4X8NzvnC197AK2HOy7baZrQGFuoLacPHd6S4XCXRHZhlDNIaeAOy_BrMRk0RkoK724Jx9_Ju28y5zdd3_4-8Sw0BxM9mgnlggd7adsMIRD1NL-tD6J6ImuJwa9dc-j7FSkpClIna-LWvp2fXYtznVFAnEvphalj8I3pqjHQ-9ruIKZ0kfMk9oMypLDrHJ3TWkUKuRBPUmpOTdLP76SdjKPRAHJwAzmsjs8G9Vu1p5F7-vIOGFFYFDjcuWuop7c33pM1b_Ekpi2WrmSX9ANuiCBO6aSKzSv5CkIByDLus3RF1Qmx0m0sKvOqAj0rSQ==\" rel=\"nofollow\" target=\"_blank\">sseapy@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODI2YjU1ZTgtNDgwNC00M2Q2LTk0OTktOWYxNzBkN2Y2OTBmLTEwMzc1NjUtMjAyNS0xMS0wMy1lbg==\/tiny\/Corvus-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1\/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting &amp; Exposition, which is taking place December 6-9, 2025 in Orlando, FL. Details regarding the oral presentation are as follows: Session Name: 625. T Cell, NK Cell, or NK\/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell LymphomaSession Date: December 8, 2025Session Time: 10:30 AM &#8211; 12:00 PMPresentation Time: 11:15 AM &#8211; 11:30 AMPublication Number: 778Title: Final results of a phase 1 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904378","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1\/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting &amp; Exposition, which is taking place December 6-9, 2025 in Orlando, FL. Details regarding the oral presentation are as follows: Session Name: 625. T Cell, NK Cell, or NK\/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell LymphomaSession Date: December 8, 2025Session Time: 10:30 AM &#8211; 12:00 PMPresentation Time: 11:15 AM &#8211; 11:30 AMPublication Number: 778Title: Final results of a phase 1 &hellip; Continue reading &quot;Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T16:41:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\\\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition\",\"datePublished\":\"2025-11-03T16:41:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/\"},\"wordCount\":290,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/\",\"name\":\"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\\\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=\",\"datePublished\":\"2025-11-03T16:41:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\\\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/","og_locale":"en_US","og_type":"article","og_title":"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1\/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting &amp; Exposition, which is taking place December 6-9, 2025 in Orlando, FL. Details regarding the oral presentation are as follows: Session Name: 625. T Cell, NK Cell, or NK\/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell LymphomaSession Date: December 8, 2025Session Time: 10:30 AM &#8211; 12:00 PMPresentation Time: 11:15 AM &#8211; 11:30 AMPublication Number: 778Title: Final results of a phase 1 &hellip; Continue reading \"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T16:41:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition","datePublished":"2025-11-03T16:41:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/"},"wordCount":290,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/","name":"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=","datePublished":"2025-11-03T16:41:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYyMyM3MjM4MDI3IzIwMjU5OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-present-final-data-from-soquelitinib-phase-1-1b-t-cell-lymphoma-trial-at-the-67th-american-society-of-hematology-annual-meeting-exposition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1\/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904378"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904378\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}